Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- IBL Signs Licensing Contact with US Firm for Lung Cancer Type Identifying Antibody
October 25, 2011
- Daiichi Sankyo, AZ Apply for Additional Indication for Nexium for Prevention of GU, DU in Patients Given Low-Dose Aspirin
October 25, 2011
- Pfizer Japan to Split Up Domestic Manufacturing Sector to Establish New Company
October 25, 2011
- Top Drug Makers Poised to Announce 1st-Half Results: Patent Expirations Could Have Big Impact
October 25, 2011
- CMIC, Medipal Set Up Joint Venture for Orphan Drugs, Develop Alliance Model
October 24, 2011
- Sales Remain Unchanged due to Domestic Market Slump Affected by Quake: Chugai Jan-Sep 2011
October 24, 2011
- MSD, Mylan Terminate Promotional Contract for Lipovas and Renivase
October 24, 2011
- Astellas Recalls Tacrolimus in Japan, Europe After Dissolution Test Standards Unmet
October 24, 2011
- SymBio’s Bendamustine Gets NDA Approval in Taiwan
October 24, 2011
- US Baxter International Initiates PIII Clinical Trial for Blood Disorder Treatment Drug
October 24, 2011
- Otsuka Confirms Efficacy of Rotigotine for RLS in Domestic PIII Clinical Study
October 21, 2011
- Ono Upwardly Revises Sales Forecast Due to Main Product Growth
October 21, 2011
- Abbott to Separate into 2 Companies
October 21, 2011
- Chugai Tops Patent Asset Rankings, Teijin Jumps to Second Place
October 21, 2011
- No. of Latuda Prescriptions to Potentially Exceed Forecast: Nomura Securities
October 21, 2011
- Takeda Positions “Enbrel MRs” in Boosted Cooperation Efforts with Pfizer
October 20, 2011
- Otsuka to Set Up Joint Venture Company to Develop, Commercialize Pancreatic Islet Cells
October 20, 2011
- Growell to Introduce T-Point Service for Copayments of Ethical Drugs
October 20, 2011
- Sanofi Signs Comprehensive Contract with Kyoto Univ. on Life Science Research
October 19, 2011
- Takeda Initiates PIII Clinical Trials for Antidiabetic TAK-875 in US, Europe
October 19, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…